GlassScriptPhysician profile
Peter Veneziano
NPI 1811308554
$8,215.41
in general payments reported to CMS, 2019-2025
29 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,416 · 2022: $1,089 · 2023: $1,258 · 2024: $1,943 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,673 · Education: $37.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.20 |
| Education | $37.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $1,837.36 | 2021-2024 | Xiaflex, Aveed |
| Tolmar, INC. | $1,064.43 | 2023-2025 | Jatenzo |
| Endo USA, INC. | $931.85 | 2024-2025 | Xiaflex, Aveed |
| Amgen INC. | $734.24 | 2021-2025 | Repatha |
| Antares Pharma, INC. | $732.05 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $539.50 | 2022-2025 | Wegovy, Ozempic |
| Pfizer INC. | $414.12 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $349.42 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $274.99 | 2021-2024 | Nexletol |
| Urovant Sciences INC | $182.15 | 2021-2022 | |
| Lilly USA, LLC | $178.12 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $106.06 | 2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $91.21 | 2024 | |
| Heartflow, INC. | $89.51 | 2022-2024 | Ffrct |
| Astellas Pharma US INC | $89.48 | 2022-2023 | Myrbetriq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $79.38 | 2025 | Tlando |
| Acerus Pharmaceuticals Corporation | $73.14 | 2021-2022 | |
| Halozyme INC | $72.28 | 2023 | |
| Ge Healthcare | $70.29 | 2022 | |
| Azurity Pharmaceuticals, INC. | $56.49 | 2025 | Azmiro |
| Kiniksa Pharmaceuticals, LTD. | $43.88 | 2022-2023 | Arcalyst |
| Sumitomo Pharma America, INC. | $41.92 | 2023 | Gemtesa |
| Inspire Medical Systems, INC. | $33.10 | 2025 | Inspire |
| Medtronic, INC. | $27.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.89 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $23.67 | 2024 | Arcalyst |
| Neurocrine Biosciences, INC. | $22.27 | 2023 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $16.11 | 2022 | |
| Currax Pharmaceuticals LLC | $15.83 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Veneziano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.